12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sovaprevir: Interim Phase II data

Interim data from 30 evaluable treatment-naïve patients with chronic HCV genotype 1 infection in the 12-week, double-blind, placebo-controlled, international Phase II 007 trial showed that 100% of patients with HCV genotype 1b infection who received 200 (n=4) or 400 (n=4) mg sovaprevir plus ACH-3102 and ribavirin achieved a rapid virologic response (RVR), defined as HCV RNA levels <10 IU/mL, at week 4. In patients with HCV genotype 1a infection, low-dose sovaprevir plus ACH-3102 and ribavirin led to an RVR rate of 80%...

Read the full 399 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >